# PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

Study · id `cardio:ct-nct05313165` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05313165](<https://clinicaltrials.gov/study/NCT05313165>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05313165

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT05313165. Allocation not applicable; no masking; primary purpose treatment. Start 2022-12-22 (actual); primary completion 2027-05-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT05313165, source copy `cardio:ctgov-nct05313165-2026-04-16`, retrieved 2026-10-31)
- Started: 2022-12-22 (actual) (ClinicalTrials.gov record NCT05313165, source copy `cardio:ctgov-nct05313165-2026-04-16`, retrieved 2026-10-31)
- Primary completion: 2027-05-01 (anticipated) (ClinicalTrials.gov record NCT05313165, source copy `cardio:ctgov-nct05313165-2026-04-16`, retrieved 2026-10-31)
- Completion: 2027-05-01 (anticipated) (ClinicalTrials.gov record NCT05313165, source copy `cardio:ctgov-nct05313165-2026-04-16`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT05313165, source copy `cardio:ctgov-nct05313165-2026-04-16`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05313165-2026-04-16`, retrieved 2026-10-31)

## The registry's words

- Brief title: PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
- Condition: Critical Limb Ischemia
- Condition: Chronic Limb-Threatening Ischemia
- Condition: Peripheral Arterial Disease
- Intervention (Device): LimFlow Stent Graft System
- Lead sponsor: LimFlow, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)

## Provenance

Content hash: 1c51a3a81824e99df8f4d83d2d88d9f9b3fe5c3ab7324fed0b5b8b05f543c842
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
